Commitment and Talent Taking Targeted Therapeutics to Market
Our strength is in our team, including the investors and leaders who make up our Board:
Prior to joining Versant, Dr. Bolzon served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Dr. Bolzon held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.
Prior to LIPCC, Dr. Neel was the Director of Research at Princess Margaret Cancer Centre (PMCC), and Professor of Medical Biophysics and Tier 1 Canada Research Chair at the University of Toronto. Prior to PMCC, he was the William B. Castle Chair of Medicine at Harvard Medical School. Ben holds a PhD in Viral Oncology from Rockefeller University, and an MD from Cornell University.
Dr. Vickers obtained his PhD in Biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Prior to joining Versant, Dr. Larson was the co-founding CEO of Tornado Medical Systems, a revenue stage scientific and medical instruments company with product lines in high performance Raman spectroscopy and optical coherence tomography. He began his professional career as a management consultant with McKinsey & Company, serving clients in the healthcare and technology sectors as an Associate Principal in the firm.
Dr. Larson received his PhD in Biophysics from Stanford University, where he studied as a James H. Clark Graduate Fellow. He received his MSc in Molecular and Medical Genetics from the University of Toronto.